Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Y-Mabs Therapeutics Inc chart...

About the Company

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Exchange

NASDAQ

Website

ymabs.com

$40M

Total Revenue

120

Employees

$655M

Market Capitalization

-24.38

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $YMAB News

Y-mAbs Therapeutics CFO Bo Kruse To Retire

4d ago, source:

Biopharmaceutical company Y-mAbs Therapeutics, Inc. (YMAB) announced Thursday that Chief Financial Officer Bo Kruse has notified the ...

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

4d ago, source: Business Insider

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...

Y-mAbs Therapeutics Inc YMAB

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

25d ago, source: Hosted on MSN

For the last reported quarter, it was expected that Y-mAbs Therapeutics, Inc. Would post a loss of $0.16 per share when it actually produced a loss of $0.18, delivering a surprise of -12.50%.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript

15d ago, source: Yahoo Finance

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript March 1, 2024 Y-mAbs Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call Transcript

17d ago, source: Seeking Alpha

Good morning and welcome to the Y-mAbs Therapeutics Earnings Conference Call for the Fourth Quarter and Full Year of 2023. At this time, all participants are in a listen-only mode. Instructions ...

Y-mAbs Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Y-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

4d ago, source:

Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...